AUTOIMMUNITY

A Global and Growing Health Challenge
Autoimmune diseases represent one of the fastest-growing therapeutic areas worldwide, affecting an estimated 3–10% of the global population. Despite this high burden, current treatment strategies remain largely focused on symptom management rather than addressing the root cause of disease.
Autoimmune diseases are complex, chronic, and costly. They often require lifelong care, involve multiple medical specialties, and are associated with high indirect healthcare costs and significant impacts on quality of life. Women are disproportionately affected, and incidence rates are steadily increasing across all regions.
A Market with Major Unmet Medical Needs
The autoimmune therapeutics market is projected to reach $250 billion by 2035 and continues to expand across multiple therapeutic areas:
- Dermatology (Psoriasis, Vitiligo, Alopecia): +78% growth in the next decade
- Gastroenterology (Celiac Disease, Crohn’s, Ulcerative Colitis): +36% growth in the next decade
- Rheumatology (RA, Lupus, Psoriatic Arthritis): +43% growth in the next decade
- Endocrinology (Type 1 Diabetes, Hashimoto’s): stable growth in the next decade
- Neurology (Multiple Sclerosis): +40% growth in the next decade
This broad and expanding market underscores the urgent need for innovative therapies that go beyond temporary relief.

A Different Path: ImmuPharma’s Curative Approach

Unlike most current therapies, which focus on controlling inflammation or modulating symptoms, ImmuPharma’s strategy is centered on addressing the underlying mechanisms driving autoimmunity.
Through our proprietary P140 technology, we aim to:
- Identify and target specific immune dysregulations,
- Restore immune tolerance rather than suppress immunity,
- Offer disease-modifying — potentially curative — solutions.
This approach not only has the potential to transform patient outcomes but also to reshape the economics of autoimmune care, reducing reliance on chronic immunosuppressants and biologics.
Strategic Positioning
In a therapeutic landscape dominated by biologics, antibodies, and small molecules aimed at symptom control, ImmuPharma positions itself as a pioneer in root-cause–oriented therapy.
Our goal is to:
- Shift the paradigm from managing autoimmune diseases to curing them,
- Offer a companion diagnostic strategy to identify responders,
- Unlock a $250 billion global market opportunity through targeted, precision medicine.


Our Vision
The autoimmune therapeutics market is projected to reach $250 billion by 2035 and We believe that autoimmune diseases can be treated at their source — not just managed. By combining scientific innovation, strategic focus, and a patient-centered vision, ImmuPharma is building a new standard of care for autoimmunity.
Our ambition is not to treat around the disease — but to end it.